Brief: ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
16/12/2021 12:18
Dec 16 (Reuters) - ProQR Therapeutics NV PRQR.O :
* PROQR ANNOUNCES FIRST PATIENTS DOSED IN PHASE 2/3 PIVOTAL
TRIALS
OF QR-421A FOR USH2A MEDIATED RETINITIS PIGMENTOSA
Source text for Eikon: ID:nGNX9Tbgym
Further company coverage: PRQR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on ProQR Therapeutics NV
See all newsProQR Therapeutics NV reports results for the quarter ended June 30 - Earnings Summary
ProQR Q2 revenue more than doubles
Brief: ProQR Therapeutics Q2 EPS EUR -0.08
ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview
ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview